OJRA  Vol.3 No.3 , August 2013
Tuberculin Skin Reaction among Healthy People and Patients with Arthritis in the Southern Israeli Region*
Abstract: Introduction: Reactivation of latent tuberculosis is a major complication of tumor necrosis factor alpha (TNF-alpha) inhibitors. Therefore, screening for latent TB is recommended before initiation of this treatment. The aim of the study was to compare Tuberculosis skin test (TST) size reaction between healthy people and patients, with Rheumatoid arthritis (RA), Ankylosising spondylitis (AnS) and Psoriatic arthritis (PsA). Patients and Methods: Results of TST of 133 healthy subjects were compared with the results of TST of 79 patients, suffering from RA, AnS and PsA. A χ2 test was used to compare the difference between the groups. A value of p < 0.05 was considered significant. Active tuberculosis (TB) was excluded by chest X-ray and through patient’s history. The results of TST reaction were grouped according to the CDC’s (Centers for Disease Control and prevention) recommendation, e.g. 0 - 4 mm, 5 - 9 mm, 10 - 15 mm and >15 mm. Results: Among RA patients 80% received Methotrexate (MTX), 50% Prednisone and 20% other DMARDs. 20% of patients suffering from AnS received MTX, 80%—NSAIDs, and among patients with PsA 70% received MTX, 30%—Salazopirin. There was no significant difference in history of bacilli Calmette-Guerine vaccination between the groups. There was no significant difference in TST reaction distribution between healthy subjects and patients with RA—p > 0.5. TST reaction distribution differed significantly between healthy people and AnS (p < 0.05) and PsA (p < 0.001) patients. The overall tendency in these two patients’ groups was towards high positive TST, especially among PsA patients. Conclusion: Our results showed that RA patients may present TST reaction as healthy people. The high percent of our AnS and PsA patients that showed TST reaction above15 mmneed further exploration. We conclude that it may be not appropriate to use TST to recognize LTBI in our population.
Cite this paper: T. Reitblat, Z. Weiler, L. Djin, N. Polyakov, G. Reifman and A. Reitblat, "Tuberculin Skin Reaction among Healthy People and Patients with Arthritis in the Southern Israeli Region*," Open Journal of Rheumatology and Autoimmune Diseases, Vol. 3 No. 3, 2013, pp. 135-139. doi: 10.4236/ojra.2013.33021.

[1]   M. C. Raviglione, D. E. Snider Jr. and A. Kochi, “Global Epidemiology of Tuberculosis. Morbidity and Mortality of a Worldwide Epidemic,” Journal of the American Medical Association, Vol. 273, No. 3, 1995, pp. 220-226. doi:10.1001/jama.1995.03520270054031

[2]   G. Kaplan and V. H. Freedman, “The Role of Cytokines in the Immune Response to Tuberculosis,” Research in Immunology, Vol. 147, 1996, pp. 565-572. doi:10.1016/S0923-2494(97)85223-6

[3]   M. Denis, “Tumor Necrosis Factor and Granulocyte Macrophage-Colony Stimulating Factor Stimulate Human Macrophages to Restrict Growth of Virulent Mycobacterium avium and to Kill a Virulent M. avium: Killing Effector Mechanism Depends on the Generation of Reactive Nitrogen Intermediates,” Journal of Leukocyte Biology, Vol. 49, No. 4, 1991, pp. 380-387.

[4]   V. Kindler, A.-P. Sappino, G. E. Grau, et al., “The Inducing Role of Tumor Necrosis Factor in the Development of Bactericidal Granulomas during BCG Infection,” Cell, Vol. 56, No. 5, 1989, pp. 731-740. doi:10.1016/0092-8674(89)90676-4

[5]   T. Ellerin, R. H. Rubin and M. E. Weinblatt, “Infections and Anti-Tumor Necrosis Factor Alpha Therapy,” Arthritis & Rheumatism, Vol. 48, No. 11, 2003, pp. 3013-3022. doi:10.1002/art.11301

[6]   Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection, MMWR ATS/CDC Statement Committee on Latent Tuberculosis Infection, June 2000.

[7]   E. C. Keystone, K. A. Papp and W. Wobeser, “Challenges in Diagnosing Latent Tuberculosis Infection in Patients Treated with Tumor Necrosis Factor Antagonists,” The Journal of Rheumatology, Vol. 38, No. 7, 2011, pp. 1234-1243. doi:10.3899/jrheum.100623

[8]   D. Ponce de León, E. Acevedo-Vásquez, A. Sánchez-Torres, et al., “Attenuated Response to Purified Protein Derivative in Patients with Rheumatoid Arthritis: Study in a Population with a High Prevalence of Tuberculosis,” Annals of the Rheumatic Diseases, Vol. 64, No. 9, 2005, pp. 1360-1361. doi:10.1136/ard.2004.029041

[9]   J. Keane and B. Bresnihan, “Tuberculosis Reactivation during Immunosuppressive Therapy in Rheumatic Diseases: Diagnostic and Therapeutic Strategies,” Current Opinion in Rheumatology, Vol. 20, No. 4, 2008, pp. 443-449. doi:10.1097/BOR.0b013e3283025ec2

[10]   G. Matulis, P. Jüni, P. M. Villiger and S. D. Gadola, “Detection of Latent Tuberculosis in Immunosuppressed Patients with Autoimmune Diseases: Performance of a Mycobacterium Tuberculosis Antigen-Specific Interferon Gamma Assay,” Annals of the Rheumatic Diseases, Vol. 67, No. 1, 2008, pp. 84-90. doi:10.1136/ard.2007.070789

[11]   I. Roitt, J. Brostoff and D. Male, “Hypersensitivity Type IV,” In: L. Cook, Ed., Immunology, 4th Edition, Mosby, Barcelona, 1998, p. 255.

[12]   C. A. Black, “Delayed Type Hypersensitivity: Current Theories with an Historic Perspective,” Dermatology Online Journal, Vol. 5, No. 1, 1999, p. 7.

[13]   A. J. Quayle, P. Chomarat, P. Miossec, et al., “Rheumatoid inflammatory T-cell clones express mostly Th1 but also Th2 and mixed (Th0-like) cytokine patterns,” Scandinavian Journal of Immunology, Vol. 38, No. 1, 1993, pp. 75-82. doi:10.1111/j.1365-3083.1993.tb01696.x

[14]   J. F. Schlaak, M. Buslau, W. Jochum, et al., “T Cells Involved in Psoriasis Vulgaris Belong to the Th1 Subset,” Journal of Investigative Dermatology, Vol. 102, No. 2, 1994, pp. 145-149. doi:10.1111/1523-1747.ep12371752

[15]   I. Sezer, H. Kocabas, M. A. Melikoglu, et al., “Positiveness of Purified Protein Derivatives in Rheumatoid Arthritis Patients Who Are Not Receiving Immunosuppressive Therapy,” Clinical Rheumatology, Vol. 28, No. 1, 2009, pp. 53-57. doi:10.1007/s10067-008-0982-1

[16]   K. H. Lee, S. Y. Jung, Y. J. Ha, et al., “Tuberculin Reaction Is Not Attenuated in Patients with Rheumatoid Arthritis Living in a Region with Intermediate Burden of Tuberculosis,” Rheumatology International, Vol. 32, No. 5, 2012, pp. 1421-1424. doi:10.1007/s00296-011-1889-8

[17]   J. D. Greenberg, S. M. Reddy, S. G. Schloss, et al., “Comparison of an in Vitro Tuberculosis Interferon-Gamma Assay with Delayed-Type Hypersensitivity Testing for Detection of Latent Mycobacterium tuberculosis: A Pilot Study in Rheumatoid Arthritis,” The Journal of Rheumatology, Vol. 35, No. 5, 2008, pp. 770-775.

[18]   I. D. Bassukas, M. Kosmidou, G. Gaitanis, et al., “Patients with Psoriasis Are More Likely to Be Treated for Latent Tuberculosis Infection Prior to Biologics than Patients with Inflammatory Bowel Disease,” Acta Dermato-Venereologica, Vol. 91, No. 4, 2011, pp. 444-446. doi:10.2340/00015555-1106

[19]   G. Tsiouri, G. Gaitanis, D. Kiorpelidou, et al., “Tuberculin Skin Test Overestimates Tuberculosis Hypersensitivity in Adult Patients with Psoriasis,” Dermatology, Vol. 219, No. 2, 2009, pp. 119-125. doi:10.1159/000222431

[20]   C. A. Nobre, M. R. Callado, J. R. Lima, et al., “Tuberculosis Infection in Rheumatic Patients with Infliximab Therapy: Experience with 157 Patients,” Rheumatology International, Vol. 32, No. 9, 2012, pp. 2769-2775. doi:10.1007/s00296-011-2017-5

[21]   O. N. Pamuk, Y. Yesil, S. Donmez, et al., “The Results of Purified Protein Derivative Test in Ankylosing Spondylitis Patients: Clinical Features, HRCT Results and Relationship with TNF-Blocker Usage,” Rheumatology International, Vol. 29, No. 2, 2008, pp. 179-183. doi:10.1007/s00296-008-0665-x

[22]   N. Inanc, S. Z. Aydin, S. Karakurt, et al., “Agreement between Quantiferon-TB Gold Test and Tuberculin Skin Test in the Identification of Latent Tuberculosis Infection in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis,” The Journal of Rheumatology, Vol. 36, No. 12, 2009, pp. 2675-2681. doi:10.3899/jrheum.090268